{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4"},{"groupId":"OG001","value":"1.5"}]}],"title":"Ischemic heart disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5"},{"groupId":"OG001","value":"0.7"}]}],"title":"Cardiac failures"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6"},{"groupId":"OG001","value":"1.5"}]}],"title":"Cerebrovascular accidents"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2"},{"groupId":"OG001","value":"1.2"}]}],"title":"Thromboembolic events"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2049"},{"groupId":"OG001","value":"2062"}],"units":"Participants"}],"description":"The incidence of ischemic heart disease, cardiac failures, cerebrovascular accidents and thromboembolic events was analyzed.","groups":[{"description":"2.5 mg by mouth (p.o.) once daily","id":"OG000","title":"Letrozole"},{"description":"1 mg p.o. once daily","id":"OG001","title":"Anastrozole"}],"paramType":"NUMBER","populationDescription":"Safety Set: The safety set included randomized participants who received at least one of study medication and had at least one post baseline assessment.","reportingStatus":"POSTED","timeFrame":"84 months","title":"Percentage of Participants Who Experienced Cardiovascular Events","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}